GLP-1

ClinicalJune 22, 2026

Study on GLP-1 and Lifestyle Interventions in Pediatric Obesity Management

A study led by the University of Minnesota aims to evaluate the effectiveness of health behavior and lifestyle treatment in conjunction with GLP-1 medications for adolescents with obesity.

Companies

Assets

Recent signals(10)

MHRA Issues Guidance on Safe Use of GLP-1 Weight Loss Medicines

Lilly Q1 2026 Revenue Up 56%, Raises Full Year Guidance

Study on Noom Program's Impact on GLP-1 Medication Users

Hoffmann-La Roche's Enicepatide Trial Targets Obesity and Type 2 Diabetes

Semaglutide tablet approved in the UK for weight loss

Study on GLP-1 and Lifestyle Interventions in Pediatric Obesity Management

Lilly's Foundayo Shows Significant Weight Loss in Menopausal Women

Lilly's Foundayo shows superior A1C reduction and weight loss in pivotal diabetes trials

Roche Advances Obesity Portfolio with Promising Phase II Data on Enicepatide and Petrelintide

Roche Advances Obesity Portfolio with Promising Phase II Data for Enicepatide and Petrelintide

Upcoming catalysts

Indications

Get signals before the market moves